Dr. Eugene Pietzak, MD
Claim this profileMemorial Sloan Kettering Cancer Center (All Protocol Activities)
Area of expertise
Bladder Cancer
Eugene Pietzak, MD has run 6 trials for Bladder Cancer. Some of their research focus areas include:
FGFR3 Mutation
Eugene Pietzak, MD has run 1 trial for FGFR3 Mutation. Some of their research focus areas include:
Affiliated Hospitals
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Memorial Sloan Kettering Cancer Center
Clinical Trials Eugene Pietzak, MD is currently running
Padeliporfin VTP
for Bladder Cancer
This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients will be treated with padeliporfin VTP in two phases: an Induction Treatment Phase and a Maintenance Treatment Phase and will be followed up for up to an additional 48 months in the long term (non intervention) follow up phase with the specific duration depending on the patient's response to treatment
Recruiting
2 awards
Phase 3
14 criteria
2141-V11
for Bladder Cancer
This trial is testing a new drug called 2141-V11 in people with bladder cancer that didn't respond to other treatments and who won't have surgery. The drug is delivered directly into the bladder to see if it is safe.
Recruiting
1 award
Phase 1
17 criteria
More about Eugene Pietzak, MD
Clinical Trial Related
7 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Eugene Pietzak, MD has experience with
- Bacillus Calmette-Guérin (BCG)
- Gemcitabine
- Erdafitinib
- Pembrolizumab (MK-3475)
- Padeliporfin VTP
- 2141-V11
Breakdown of trials Eugene Pietzak, MD has run
Bladder Cancer
FGFR3 Mutation
Kidney Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Eugene Pietzak, MD specialize in?
Eugene Pietzak, MD focuses on Bladder Cancer and FGFR3 Mutation. In particular, much of their work with Bladder Cancer has involved FGFR3 positive patients, or patients who are Stage II.
Is Eugene Pietzak, MD currently recruiting for clinical trials?
Yes, Eugene Pietzak, MD is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Eugene Pietzak, MD has studied deeply?
Yes, Eugene Pietzak, MD has studied treatments such as Bacillus Calmette-Guérin (BCG), Gemcitabine, Erdafitinib.
What is the best way to schedule an appointment with Eugene Pietzak, MD?
Apply for one of the trials that Eugene Pietzak, MD is conducting.
What is the office address of Eugene Pietzak, MD?
The office of Eugene Pietzak, MD is located at: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center (All Protocol Activities).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.